back to US directory
us clinical guidance

Cognitive decline and dementia diagnostic evaluation

US patient-centered recognition, tiered evaluation, collateral history, diagnosis disclosure and early care planning for suspected dementia.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Middle-aged and older adults with patient-, care-partner- or clinician-observed cognitive, behavioral or functional decline. The 2024 DETeCD-ADRD guideline addresses diagnostic evaluation, testing, counseling and disclosure rather than every dementia medicine or long-term-care intervention. Acute delirium, intoxication, head injury and rapidly progressive neurologic illness require separate urgent pathways.
sources for this section:DETeCD-ADRD 2024

The Bottom Line

  • Initiate a structured evaluation when the patient, a knowledgeable informant or a clinician reports meaningful cognitive, behavioral or functional change; do not dismiss decline as normal aging without assessment.
  • Define the cognitive鈥揵ehavioral syndrome and functional stage before assigning an etiology, using patient history, collateral information, examination and validated cognitive and functional measures.
  • Investigate medical, neurologic, psychiatric, medication and sensory contributors with a tiered laboratory and structural-brain-imaging approach, escalating biomarkers only when they answer a specific question.
  • Disclose findings and uncertainty compassionately to the patient and chosen care partner, assess understanding and preferences, and connect the diagnosis to a practical care and safety plan.
sources for this section:DETeCD-ADRD 2024

Practical clinical workflow

1
Clarify onset and trajectory, affected domains, instrumental and basic activities, mood, sleep, substance use, medicines, education, language, culture and sensory impairment; obtain collateral history with permission.
2
Perform neurologic and general examination, assess delirium and depression, use a validated cognitive instrument interpreted in context and evaluate decision-making capacity for the decision at hand.
3
Order core laboratory and structural imaging guided by the DETeCD tier, then refer early-onset, rapidly progressive, atypical, movement-associated or diagnostically uncertain syndromes to specialty care.
4
After disclosure, address medication simplification, driving and firearm safety, falls, finances, advance care planning, caregiver strain, community resources and follow-up while preserving autonomy.
sources for this section:DETeCD-ADRD 2024

Safety boundaries and escalation

  • Acute fluctuating inattention, altered arousal, fever, focal deficit, new seizure or abrupt functional collapse suggests delirium, stroke or another emergency rather than routine dementia progression.
  • Rapid progression over weeks or months, early gait or motor findings, prominent personality change or unusual neurologic signs requires expedited specialist investigation.
  • Assess exploitation, self-neglect, unsafe driving, wandering, medication error, firearm access and caregiver harm directly and follow state safeguarding or reporting duties.
  • Do not order amyloid, tau, genetic or blood biomarkers as indiscriminate screening; use validated tests in the population and setting supported by current specialty guidance and counseling.
sources for this section:DETeCD-ADRD 2024

Localization

DETeCD-ADRD is a new US diagnostic guideline. Capacity, driving reporting, adult-protective-services duties, advance directives and access to biomarkers vary by state and payer.
sources for this section:DETeCD-ADRD 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Alzheimer's Association DETeCD-ADRD Clinical Practice Guideline WorkgroupClinical Practice Guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders: Primary Care Executive SummaryDOI 10.1002/alz.14333 路 published 2024-12-23 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.